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1568-9972/© 2017 The Author(s). Published by Elsevier Ba b s t r a c ta r t i c l e i n f oAvailable online 2 December 2017 Carbamylation and citrullination are both post-translationalmodifications againstwhich (auto)antibodies can be
detected in sera of rheumatoid arthritis (RA) patients. Carbamylation is the chemicalmodification of a lysine into
a homocitrulline, whereas citrullination is an enzymatic conversion of an arginine into a citrulline. It is difficult to
distinguish between the two resulting amino acids due to similarities in structure. However, differentiation be-
tween citrulline and homocitrulline is important to understand the antigens that induce antibody production
and to determine which modified antigens are present in target tissues.
We have observed in literature that conclusions are frequently drawn regarding the citrullination or
carbamylation of proteins based on reagents that are not able to distinguish between these two modifications.
Therefore,we have analyzed awide spectrumofmethods and describe herewhichmethodwe considermost op-
timal to distinguish between citrulline and homocitrulline.
We have produced several carbamylated and citrullinated proteins and investigated the specificity of (commer-
cial) antibodies by both ELISA and western blot. Furthermore, detection methods based on chemical modifica-
tions, such as the anti-modified citrulline-“Senshu” method and also mass spectrometry were investigated for
their capacity to distinguish between carbamylation and citrullination.
We observed that some antibodies are able to distinguish between carbamylation and citrullination, but an over-
lap in reactivity is often present in the commercially available anti-citrulline antibodies. Finally, we conclude that
the use of mass spectrometry is currently essential to differentiate between citrullinated and carbamylated pro-
teins present in complex biological samples.
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The presence of anti-citrullinated protein antibodies (ACPA) is a
well-known phenomenon in rheumatoid arthritis (RA). These autoanti-
bodies associate with disease development in RA patients [1,2] and
were recently added to the classification criteria for RA [3,4]. ACPA tar-
get proteins that have undergone a post-translational modification,
citrullination, which is the conversion of an arginine into a citrulline.
This is an enzymatic reaction that is facilitated by peptidyl arginine
deiminases (PAD) [5]. There are several PAD enzymes with the capacity
to citrullinate proteins. These PAD enzymes are often present in the cell,
in which they can citrullinate e.g. histones and play a role in gene regu-
lation [6]. Under certain inflammatory conditions, PAD is thought to be
released from cells, which may induce local extracellular citrullination
[7]. Furthermore, protein citrullination occurs in different physiological
processes as evidenced by the presence of several citrullinated proteins
in the central nervous system or citrullinated forms of keratin and
filaggrin in the skin [8,9].
When compared to ACPA, anti-carbamylated protein antibodies
(anti-CarP antibodies) were discovered more recently [10]. Anti-CarP
antibodies are increased in RA patients [10–14] and they associate
with a more severe disease course as well [10,12]. However, anti-CarP
antibodies are a different autoantibody system, with a limited cross-
reactivity towards citrullinated respectively carbamylated proteins
[15,16]. In human serum samples of RA patients, often both ACPA and
anti-CarP antibodies are present. On the other hand, animal models,
such as collagen-induced arthritis in mice or primates are characterized
by the absence of ACPA, while anti-CarP antibodies can readily be de-
tected [17,32]. Furthermore, anti-CarP antibodies have been detected
in non-RApatients aswell, although at lower percentages than in RA pa-
tients [13,18,19]. Anti-CarP antibodies target proteins that contain
homocitrullines, also called carbamylated proteins. Carbamylation is a
chemical reaction that is carried out in the presence of cyanate. Both
PAD enzymes and cyanate can be increased upon chronic inflammation,
which might therefore increase the formation of citrulline and
homocitrulline residues. The increase in cyanate during inflammation
can be due to the conversion of thiocyanate into cyanate by
myeloperoxidase [20]. Furthermore, cyanate can be increased in renal
failure, due to its equilibrium with urea [21–23]. Smoking is also
thought to increase the presence of cyanate and therefore
carbamylation [24].
Although there are similarities between the two autoantibody sys-
tems (ACPA and anti-CarP antibodies), they do target two different
post-translational modifications. As the name of both residues already
implies, the difference between a citrulline and a homocitrulline is
small.We therefore often observe situations inwhich thedistinctionbe-
tween a citrulline and a homocitrulline is difficult. However, it is impor-
tant to distinguish between the two post-translational modifications in
order to further investigate the role of ACPA and anti-CarP antibodies
separately. Although both antibodies can be detected years before dis-
ease onset [2,12], it is at the moment not clear whether the RA autoan-
tibody response is first initiated against a citrulline or a homocitrulline
residue. In the future, it may therefore be important to gain a deeper un-
derstanding of these modifications, especially when further investigat-
ing the possible pathogenesis of RA.Here,we describe themost specificmethods to determinewhether a
modification is a citrulline or a homocitrulline. We show the that use of
polyclonal andmonoclonal antibodies for ELISA or western blot, are not
always sufficiently specific to make formal conclusions on the nature of
the modified proteins. Furthermore, we discuss the use of the chemical
“Senshu” modification in different settings and conclude with the pit-
falls in detecting citrulline and homocitrulline usingmass spectrometry
(MS). In the end,we conclude that antibodies or other (chemical) detec-
tionmethods are suitable to determinewhether an in vitromodification
was successful, but that MS is required to distinguish between the two
amino acids in more complex settings.
2. Description of different methods to measure carbamylation and
citrullination
2.1. Antigens and modifications
For our analyses we have used citrullinated and carbamylated ver-
sions of three antigens, namely fetal calf serum (FCS, Bodinco), human
serum albumin (HSA, Sigma) and human fibrinogen (Fib, Sigma). The
non-modified counterparts served as controls. Carbamylation of pro-
teins was carried out by incubating the protein in a final concentration
of 1 M potassium cyanate (KOCN, Sigma) diluted in PBS. The protein
concentration was between 2 mg/ml and 5 mg/ml, depending on the
protein involved. This mixture was incubated overnight at 37 °C, after
which the solution was dialyzed against PBS for 48 h at 4 °C. During
this time, the PBS was refreshed at least 5 times. Citrullination of HSA,
Fib and FCS was carried out by diluting the protein in 0.1 M Tris-HCL,
5 mM DTT and 10 mM CaCl2. For each mg of protein 10 units of PAD
(Sigma) were added and the solution was incubated at 53 °C for 6 h.
The presence of citrullination and or carbamylation was confirmed by
both ELISA and MS.
2.2. Commercially available antibodies
Four commercially available anti-citrulline antibodies and two anti-
homocitrulline antibodies were used in these experiments. The anti-
citrulline antibodies were mouse monoclonal anti-citrulline antibody,
clone F95 (Millipore, MABN328), rabbit polyclonal anti-citrulline anti-
body (Upstate, 07-377), rabbit polyclonal anti-citrulline antibody
(Abcam, ab100932) and rabbit polyclonal anti-citrulline antibody
(Abcam, ab6464). The anti-homocitrulline antibodies were goat poly-
clonal anti-homocitrulline antibody (Abcam, ab175576) and rabbit
polyclonal anti-homocitrulline antibody (Cell biolabs, STA-078). As sec-
ondary antibodies, to detect binding of the antibodies described above,
the following antibodies were used: goat anti-rabbit Ig-HRP (DAKO,
P0214), goat anti-mouse Ig-HRP (DAKO, P0447) and rabbit anti-goat
Ig-HRP (DAKO, P0449). Monoclonal antibody binding to modified pro-
teins was detected with goat anti-mouse IgG2a-HRP (Southern biotech,
1080-05) or rabbit anti-human IgG-HRP (DAKO, P0214).
2.3. Monoclonal antibodies
The monoclonal antibody targeting anti-CarP antibodies was made
previously [16]. Antibody-producing hybridomas were made by fusing
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PEG1500 (Roche).
The monoclonal anti-citrulline antibody was made previously by
culturing single B cells from an ACPA-positive RA patient, enriched via
FACS sorting using a citrullinated fibrinogen peptide tetramer staining,
for 14 days followed by screening of supernatants for production of an-
tibodies reactive to citrullinated fibrinogen [25].Variable domain se-
quences were obtained from RACE PCR products, and synthetic DNA
constructs cloned into a pcDNA3.1 vector for protein expression in Free-
style HEK293 cells.
2.4. ELISA
Nunc Maxisorp plates (Thermo scientific) were coated with 10 μg/
ml of the non-modified or modified antigens and incubated overnight
at 4 °C. Plates were blocked with PBS with 1% bovine serum albumin
(BSA, Sigma) for at least 6 h at 4 °C, followed by addition of the primary
antibody in different concentrations, which were diluted in PBS, 1% BSA
and 0.05% Tween20 (Sigma). The primary antibodywas incubated over-
night at 4 °C. The secondary antibodywas incubated for 3.5 h at 4 °C. The
presence of antibody-bound HRP was detected with ABTS (2,2′-azino-
bis(3-ethylbenzothiazoline-6-sulphonic acid)). In between the different
steps, plates were washed 3× with PBS 0.05% Tween20.
2.5. Western blot
5 μg of (modified) FCS and 2 μg of (modified) HSA or fibrinogenwas
loaded on a 4%–15% gel (Bio-Rad) for gel electrophoresis. The Pageruler
Plus Prestained protein ladder (Thermo Scientific, 26619)was used as a
size comparison for the samples. Protein transferwas carried out using a
Bio-Rad system and PVDF transfer packs (Bio-Rad, 170-4156) Mem-
branes were blocked for 1 h with PBS, 3% skim milk powder (Sigma)
and 0.05% Tween 20 at room temperature (rt). Primary antibodies
were incubated for 2 h at rt and secondary antibodies were incubated
for 1 h at rt. Washing steps were carried out with PBS 0.05% Tween20.
The HRP signal was developed using ECL (GE healthcare, RPN2109).
2.6. Senshu method
The so-called anti-modified citrulline-“Senshu”-method was carried
out as described [15,26]. The initial steps are similar as for the western
blotting procedure. However, after protein transfer, the membrane is
blocked in 0.1% ovalbumin for 15 min at rt and the membrane is fixed
with 4% paraformaldehyde for 15 min at rt. After each of these two
steps, milliQ is used for washing. Solution A, consisting of 0.25% FeCl3,
25% H2SO4 and 20% H3PO4 and solution B consisting of 0.5%
butanedione monoxime, 0.25% antipyrine and 0.5 M acetic acid are
both diluted in milliQ. The solutions are mixed 1:1 and incubated over-
night at 37 °C with the membrane, while shaking. The blot is blocked
with PBS, 5% skim milk powder and 0.05% Tween20 for 1 h at rt.
Human anti-modified citrulline antibody (Modiquest, MQR2.601) is in-
cubated at 1 μg/ml for 3 h at rt. As a secondary antibody, rabbit-anti-
human IgG-HRP was used (DAKO, P0214). The “blocking buffer” is
also used for the antibody dilutions. Washing steps were carried out
with PBS 0.05% Tween20, unless mentioned otherwise. The HRP signal
was detected using ECL (enhanced chemiluminescence, GEHealthcare).
3. Results
3.1. All tested commercial anti-citrulline antibodies also recognize
carbamylated proteins in ELISA
We tested the reactivity of 6 commercially available antibodies, of
which 2 are reported to be specific for homocitrulline and 4 are reported
to be specific for citrulline, against three carbamylated, citrullinated or
non-modified proteins in ELISA. The antigens used were FCS, HSA andFib. The antibodies targeting homocitrullines display a binding pattern
rather specific for carbamylated proteins, although low reactivity
against citrullinated proteins is also observed for one of the antibodies
(Fig. 1A).
Out of the 4 anti-citrulline antibodies, all 4 show, next to reactivity
against citrullinated proteins, also extensive reactivity against
carbamylated proteins (Fig. 1B). Often, the reactivity observed towards
the carbamylated version of the protein is even higher than the reactiv-
ity towards the citrullinated version of the same protein. Reactivity to
the non-modified protein was hardly present in all cases.
3.2. Antibodies can be specific for citrulline or homocitrulline in ELISA
Although we observed that many of the commercial antibodies are
not specific for citrulline or homocitrulline, this does not directly impli-
cate that antibodies in general cannot be specific for these post-
translational modifications. Previously, we have shown for human anti-
bodies in a polyclonal setting that antibody specificity for either
carbamylation or citrullination does exist [15]. Here we also show this
specificity for a monoclonal antibody response. We have previously ac-
quired a human ACPA monoclonal antibody and generated a mouse
anti-CarP monoclonal antibody, which we also tested in a similar
ELISA setting as the commercial antibodies (Fig. 2). The results indicate
that the ACPA monoclonal is very specific for citrullinated proteins,
while the anti-CarP monoclonal also shows some reactivity towards
the citrullinated proteins. This indicates that specificity towards citrul-
line or homocitrulline does exist, but is dependent on the antibodies
that are used.
3.3. Detection of carbamylated and citrullinated proteins in western blot
shows similar specificity profiles as in ELISA
Besides ELISA, there are also other methods to detect carbamylated
or citrullinated proteins. The anti-citrulline and anti-homocitrulline an-
tibody that seemed to be most specific were selected and used for fur-
ther experiments in western blot (Fig. 3a–b), using the same antigens
as in ELISA. These data confirm that the anti-citrulline antibody is not
specific for citrulline alone, while the anti-homocitrulline antibody
does not seem to react with the citrullinated proteins.
Combined, these data therefore indicate that the antibodies that are
thought to specifically target citrullinated proteins should be used with
caution.
3.4. The Senshu method is also not able to distinguish between citrulline
and homocitrulline residues
Another method to detect either citrulline or homocitrulline is the
anti-modified citrulline (AMC)-Senshu method [26]. This method was
initially used for the detection of citrullinated proteins. But more recent
studies have indicated that next to citrulline also homocitrulline ismod-
ified in exactly the sameway [15,27]. Thismethod is based on the chem-
ical modification of citrulline and homocitrulline residues, after which
this additional chemical modification can be recognized by antibodies.
This is also the case for the proteins that we modified (Fig. 3c), indicat-
ing that this method is indeed not specific. The chemical modification
used for the Senshu method can also be used for 96 well-plate assays
or immunohistochemistry staining (data not shown) [28].
3.5. Mass spectrometry
Methods to detect post-translational modifications with MS were
described previously [16,29]. Distinguishing between a citrulline and a
homocitrulline residue is straightforward because both residues are
present at a different position within the protein (they are derived
from either an arginine or a citrulline). Furthermore, homocitrulline dif-
fers from citrulline by 14 Da. We have recently used this approach for
Fig. 1. Reactivity of commercial antibodies against three carbamylated and citrullinated protein. Antibody reactivity of 2 anti-homocitrulline antibodies (A) and 4 anti-citrulline antibodies
(B) against carbamylated (circle), citrullinated (square) and non-modified (triangle) proteins was determined by ELISA. The numbers on the Y-axis represent the absorbance values
measured at 415 nm, while the x-axis shows reciprocal dilution. FCS: fetal calf serum, HSA: human serum albumin, Fib: fibrinogen.
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human samples [16,29]. However, confident determination of
citrullination (ΔMCit-Arg = +1 Da), is prone to false positive assign-
ments using automated standard proteomic workflows. A number of
complicating factors (of which some may also apply for the identifica-
tion of homocitrulline residues) are briefly discussed below.
Citrullination is a sub stoichiometric post-translational modification.
Therefore, lowabundant peptides have to be analyzed in a full proteome
background. Because of their low abundance the spectral quality can be
poor. In addition, the low abundance also leads to more interferences
during precursor ion isolation, i.e. co-isolation of other species, which
leads to mixed or contaminated MS/MS spectra that are more difficult
to interpret (and more prone to wrong assignments). An extra compli-
cation is that the deamidation of an asparagine residue (Δm=+1 Da)
is rather common and has the same mass change. Therefore,
deamidation has to be included as a variable modification during the
matching of the recorded tandem mass spectra with the protein data-
base. If deamidation is not included the software can wrongly fit the
tandemmass spectrum to include e.g. a citrulline residue at an arginineposition. However, the inclusion of two variable modifications, both
leading to a+1 Damass shift, is also a further complication. A citrulline
may also be assignedwrongly at an arginine position due to inadvertent
calling and selection of the second isotope of the precursor isotope pat-
tern as the precursor mass. Finally, conversion of an arginine into a cit-
rulline makes that particular site insensitive to trypsin cleavage,
resulting in longer peptides, which generally yield less complete frag-
ment ion series as well. Of note, C-terminally citrullinated tryptic pep-
tides (protein C-terminal residue excluded), regularly ‘identified’ by
the database matching process, are a clear illustration of false positive
assignments.
In spite of the above, citrulline residues can be confidently assigned
if performed with great caution from the tandem mass spectra, e.g. as
performed before [30] in which citrullinated fibrinogen peptides in SF
were identified. Using a similar approach we identified the same
citrullinated peptides (data not shown). The best solution to correct as-
signment of tandem mass spectra is the comparison of the tentatively
identified sequences and their synthetic counterparts. It unequivocally
establishes the correctness of the tentatively assigned peptide sequence.
Fig. 3.Reactivity of two commercially available antibodies inwestern blot and a senshu on
the same proteins. Antibody reactivity of anti-citrulline antibody (Millipore MABN328)
(A) and anti-homocitrulline antibody (Cell biolabs, STA-078) (B) against carbamylated,
citrullinated and non-modified proteins was determined by western blot. The same
proteins were also used to carry out a Senshu, a chemical detection method for
carbamylation and citrullination (C).
Fig. 2. Reactivity of two monoclonal antibodies against three carbamylated and citrullinated proteins. Antibody reactivity of one human anti-citrulline monoclonal and one mouse anti-
homocitrulline monoclonal against carbamylated (circle), citrullinated (square) and non-modified (triangle) proteins was determined by ELISA. The numbers on the x-axis represent the
concentration of themonoclonal antibody. The numbers on the Y-axis represent the absorbance valuesmeasured at 415 nm. FCS: fetal calf serum, HSA: human serumalbumin, Fib: fibrinogen.
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prevent a one-by-one comparison strategy because of costs involved.
However, if investments are made in follow-up work, checking the cor-
rect identifications with synthetic peptides is strongly recommended.4. Discussion
Here we describe that many of the commercially available antibod-
ies are often not suitable for the distinction between carbamylation
and citrullination in both ELISA and western blot. Especially the tested
anti-citrulline antibodies, recognize both citrulline and homocitrulline.
Changing experimental conditions, such as buffers and incubation
times, might improve the specificity of the antibodies. However, most
other protocols thatwe applied for someof the anti-citrulline antibodies
resulted in a reduced specificity and/or sensitivity (data not shown).
Changes in experimental set-up may however influence the observed
specificity of these antibodies. We also show that the use of a monoclo-
nal antibody can result in increased specificity, indicating that antibod-
ies can be more specific for citrulline. Furthermore, the commercial
antibodies targeting carbamylation seemed to be more specific than
the commercial anti-citrulline antibodies. For all of the tested polyclonal
antibodies, a small molecule or peptide, sometimes coupled to KLHwas
used for animal immunization. Often, affinity purification was carried
out (not for AB100932 and AB6464) as well, but cross-reactivity still
seems to be present, especially for the anti-citrulline antibodies. Using
stricter protocols and negative selection for the unwanted reactivity
may result in improved specificity. However, it cannot be excluded
that these antibodies recognize other, (non-)modified proteins when
applied to a complexmixture of proteins. Therefore the use of these an-
tibodies to identify the presence of one of these two modifications in
complex biological samples is in our opinion very limited. Determina-
tion of the success of an in vitro modification, such as carbamylation
or citrullination on the other hand, would be a very useful application
for which these antibodies can be used, when the non-modified protein
is taken along as a negative control.
The use of chemical modifications, such as the Senshu method was
shown before to be insensitive for the distinction between citrulline
and homocitrulline [15,27]. Here we confirm these data and show that
although this method is very efficient in identification of the post-
translational modifications, discrimination is not possible. Another
method, using a rhodamine-phenylglyoxal probe also recognizes both
citrulline and homocitrulline residues [31].
Finally,we have discussed thatMS is a very effectivemethod to iden-
tify the presence of a citrulline or a homocitrulline. However,
141M.K. Verheul et al. / Autoimmunity Reviews 17 (2018) 136–141identification of citrullination requires additional attention to avoid
false-positive assignments.
Even though the detection of carbamylation or citrullination with
antibodies or chemical methods may not be most optimal, these
methods have often been used in the past, when the focus in the RA-
field was more on ACPA and not yet on anti-CarP antibodies. The find-
ings that most of the methods used here are also able to detect
carbamylation do not completely invalidate these previous studies.
However, it is important to retrospectively evaluate these studies
which may result in a different view on the relative role of citrullinated
versus carbamylated proteins in health and disease.
5. Conclusion
To summarize, the use of commercial antibodies or chemical modi-
fication at this point in time, is not optimal to distinguish between
carbamylation and citrullination. MS on the other hand, is a very effec-
tive method for making this distinction, at least when all pitfalls are
avoided successfully.
Take-home messages
– Many commercially available antibodies do not distinguish between
citrulline and homocitrulline.
– Chemical modifications such as the “Senshumethod”, do not distin-
guish between citrulline and homocitrulline.
– Mass spectrometry is the best method to detect the presence of
citrullination and carbamylation.
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